Cancer Discov. 2016 Aug;6(8):OF1. doi: 10.1158/2159-8290.CD-NB2016-087. Epub 2016 Jul 8.
Data from a phase I study indicate that the investigational ALK inhibitor lorlatinib is active in patients with ALK- or ROS1-positive non-small cell lung cancer, including those with brain metastases. Objective responses were seen among patients with known ALK resistance mutations who had relapsed following treatment with other tyrosine kinase inhibitors.
一项 I 期研究的数据表明，ALK 抑制剂劳拉替尼在 ALK 或 ROS1 阳性的非小细胞肺癌患者中具有活性，包括脑转移患者。在接受其他酪氨酸激酶抑制剂治疗后复发且已知存在 ALK 耐药突变的患者中观察到了客观缓解。
